Therapeutic Category:

Anti-retroviral reverse transcriptase inhibitor.


Composition:

EMDUO/SYNVIR-30EMDUO/SYNVIR-40
Each tablet contains:Each tablet contains:
Stavudine 30 mg + Lamivudine 150 mgStavudine 40 mg + Lamivudine 150 mg

Indications And Usage:

Human immunodeficiency virus (HIV) infection;


Contraindications:

Hypersensitivity to any of the components of the formulation.


Warnings:

Lactic acidosis/severe hepatomegaly with steatosis have been reported. Treatment should be discontinued in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity.


Precautions:

Should be used with caution in patients with hepatic disease, peripheral neuropathy, and patients receiving concurrent neurotoxic agents including didanosine. Dosage adjustments are required in renal failure. Antimicrobial resistance can develop when stavudine is used either alone or in combination with other agents.


Pregnancy (Category C) and Lactation:

Should be used with caution in pregnancy and lactation.


Adverse Reactions:

Peripheral neuropathy, headache, myalgia, insomnia, asthenia, skin rash (unspecified), anorexia, diarrhea, nausea/vomiting, abdominal pain, elevated hepatic enzymes, lactic acidosis, severe hepatomegaly with steatosis, hepatitis and hepatic, lipodystrophy. Neutropenia and thrombocytopenia.


Dosage And Administration:

  • Body weight > 60 kg = Emduo/Synvir-40 one tablet twice daily
  • Body weight < 60 kg = Emduo/Synvir-30 one tablet twice daily


Storage:

Store in a cool, dry and dark place.